Clinical trial
A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes
NCT02806973 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- April 30, 2015
- Enrollment
- 32 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.